Mutual Advisors LLC Takes $1.75 Million Position in GRAIL, Inc. $GRAL

Mutual Advisors LLC acquired a new position in shares of GRAIL, Inc. (NASDAQ:GRAL) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 29,577 shares of the company’s stock, valued at approximately $1,749,000.

Other large investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its holdings in GRAIL by 768.1% during the 2nd quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock worth $42,000 after buying an additional 722 shares during the last quarter. Roble Belko & Company Inc acquired a new stake in shares of GRAIL during the 2nd quarter worth about $68,000. Cypress Capital Management LLC WY purchased a new stake in GRAIL during the second quarter worth approximately $72,000. NewEdge Advisors LLC boosted its holdings in GRAIL by 390.3% in the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock valued at $45,000 after purchasing an additional 1,401 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in GRAIL by 278.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,288 shares of the company’s stock valued at $118,000 after purchasing an additional 1,684 shares in the last quarter.

GRAIL Price Performance

GRAL stock opened at $105.42 on Wednesday. The company has a market cap of $4.11 billion, a price-to-earnings ratio of -9.06 and a beta of 4.52. The company has a fifty day moving average price of $98.01 and a 200 day moving average price of $71.07. GRAIL, Inc. has a 12 month low of $20.44 and a 12 month high of $118.84.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($2.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.40) by $0.94. The company had revenue of $36.19 million for the quarter, compared to the consensus estimate of $33.83 million. GRAIL had a negative net margin of 286.43% and a negative return on equity of 15.69%. As a group, analysts anticipate that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GRAL. Canaccord Genuity Group raised their price objective on shares of GRAIL from $85.00 to $105.00 and gave the stock a “buy” rating in a report on Monday, November 17th. Guggenheim lifted their price target on shares of GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, January 22nd. Finally, Morgan Stanley raised their price objective on GRAIL from $85.00 to $110.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $105.00.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.